SJÖGREN’S · ACA
ACA-positive Sjögren’s disease
Phenotype, overlap and longitudinal risk
Anticentromere antibodies add a clinically useful dimension to Sjögren’s disease, particularly when anti-SSA is negative or vascular features complicate the picture. They do not establish systemic sclerosis, explain every symptom, or prescribe a treatment. The practical task is to connect the laboratory finding to objectively demonstrated disease, organ function and change over time.
This chapter separates evidence obtained directly in ACA-positive Sjögren’s disease from guidance for Sjögren’s generally and for established systemic sclerosis. The proposed clinical routes are an editorial synthesis, not a validated prediction model. Sources checked for this edition: 22 September 2026.
What exactly does ACA identify?
Anticentromere antibodies recognize proteins associated with centromeres and the kinetochore, including CENP-A, CENP-B and CENP-C. A laboratory result may describe an immunofluorescence pattern or reactivity to a specific antigen. These are related observations, with different analytical coverage. Anti-CENP-B positivity should not be silently relabeled as a comprehensive assay of every centromere specificity. [R01]
ACA is also an ambiguous abbreviation: here it means anticentromere antibodies, not anticardiolipin antibodies. The latter belong to a different clinical assessment. A positive centromere result alone is not a reason for an antiphospholipid syndrome diagnosis or anticoagulation.
Keep four clinical situations separate: an incidental result without established connective tissue disease; ACA-positive Sjögren’s without systemic sclerosis; Sjögren’s with findings suggesting early systemic sclerosis; and established Sjögren’s/systemic sclerosis overlap. Historical papers using “primary” or “secondary” Sjögren’s should retain their original population definitions when compared.
A marker, a mechanism and a treatment target are different concepts. ACA can help identify a clinical pattern even when its direct contribution to gland injury remains uncertain. Demonstrating an antibody in blood is not the same as demonstrating that it reaches a target, produces injury and can be neutralized to improve disease. Those additional steps require functional and interventional evidence. This distinction explains why the laboratory result can matter diagnostically without becoming the number that treatment must normalize.
For clinical communication, write the disease and phenotype explicitly—for example, “Sjögren’s disease, anti-SSA negative, confirmed centromere reactivity, Raynaud’s without established SSc.” Such a description remains interpretable when a laboratory panel or diagnostic label changes. “ACA syndrome” conceals too many distinct situations.
Read the assay before reading the prognosis
HEp-2 indirect immunofluorescence can show the ICAP AC-3 centromere pattern. Antigen-specific immunoassays, commonly including CENP-B, provide complementary information. ICAP advises antigen-specific confirmation particularly for low-titer patterns; some CENP-B-negative sera recognize other centromere proteins. [R01]
Review the actual report: date, method, reference range, numerical value or titer, staining pattern, included antigens and whether Ro52 and Ro60 were separately assessed. A result expressed in assay units cannot be compared numerically with an ANA dilution titer. Mixed patterns and an unexpected borderline result justify laboratory clarification when the answer would change care.
An assay discrepancy is a question to resolve, not evidence that either the patient or the entire laboratory panel is unreliable. Repeating an identical panel indefinitely adds little when the unresolved issue is antigen coverage or clinical attribution. Conversely, a convincing clinical phenotype should not be dismissed because one narrowly configured panel is negative.
| Laboratory situation | Useful clarification | Consequence for interpretation |
|---|---|---|
| Weak isolated CENP-B result, little clinical support | Review cutoff, platform and HEp-2 findings; consider confirmation using a complementary method | Establish whether this is a reproducible finding before broad prognostic counseling |
| Convincing AC-3 pattern, negative CENP-B | Check antigen coverage and discuss other centromere specificities with the laboratory | One negative antigen assay need not invalidate a pattern |
| ACA and SSA reported by different laboratories | Obtain the original reports, dates and Ro antigen coverage | Do not infer a biological change from different methods |
| Previously confirmed ACA remains positive | Ask whether a new analytical question exists | Persistent positivity alone does not identify treatment failure |
This table is a reasoning aid rather than an instruction to repeat every result. The value of confirmation is greatest when it resolves a discordance that would otherwise alter a consequential diagnosis or investigation. Broad reflex panels can create more ambiguous findings if no clinical question has been defined.
Four ACA/SSA profiles, four different interpretive problems
| Profile | What to establish | What the profile does not establish |
|---|---|---|
| ACA+/SSA− | Objective glandular disease, biopsy when relevant, vascular examination and assay definition | Absence of autoimmunity; automatic SSc; eligibility for an SSA-required trial |
| ACA+/SSA+ | Contributions of both serological patterns, other antibodies and actual organ findings | A fixed “double-positive syndrome” with a uniform prognosis |
| ACA−/SSA+ | Sjögren’s phenotype, systemic findings and relevant reproductive counseling | Freedom from vascular, pulmonary or other complications |
| ACA−/SSA− | Clinical probability, objective testing, biopsy quality and alternative causes | Exclusion of Sjögren’s; a diagnosis based on symptoms alone |
The table is a clinical organizing device, not a severity ranking. In the Japanese four-group study, co-positive patients shared features of the two antibody-defined groups; however, its small ACA subsets cannot establish an individual treatment response. [R05] “SSA-negative” and “seronegative” are not interchangeable when ACA or other autoantibodies are present. A study grouping all accompanying autoantibodies together also does not provide an ACA+/SSA+ analysis.
The clinically useful comparison is within a phenotype, not just between laboratory columns. For example, compare two SSA-negative people with similar objective gland disease, age and vascular findings before attributing every difference to ACA. Otherwise, selection by biopsy, accompanying antibodies or established SSc can account for an apparent “ACA effect.”
Co-positivity does not mean arithmetic addition of risks. An SSA-associated observation and an ACA-associated observation, estimated in different populations, cannot be added to produce one person’s prognosis. Document the actual features that prompted concern, including whether rheumatoid factor, low complement, cryoglobulins or a monoclonal component are present. Those findings answer different questions from the ACA/SSA pairing.
Clinical diagnosis and research classification
The 2016 ACR/EULAR classification framework gives substantial weight to anti-SSA and focal lymphocytic sialadenitis on an adequate labial biopsy. Objective ocular and salivary tests contribute separately. ACA does not substitute for anti-SSA within that framework. In an SSA-negative individual, the biopsy becomes especially important for meeting the formal classification threshold. [R02]
Classification creates reproducible research populations. Clinical diagnosis additionally requires judgment about competing explanations, disease stage, test quality and the whole phenotype. Neither a symptom questionnaire nor a positive ACA result settles that judgment. Medication effects, prior head-and-neck irradiation, infection, sarcoidosis, IgG4-related disease and other mimics matter when appropriate to the history.
Salivary gland ultrasound can strengthen or redirect the assessment but is not an interchangeable replacement for every classification item. If a research paper modifies an antibody inclusion rule, describe that modification explicitly; it does not amend the international criteria or validate an ACA-only diagnostic shortcut.
A worked classification example. In an eligible patient without an exclusion condition, anti-SSA and an adequate biopsy showing focal lymphocytic sialadenitis with focus score ≥1 each contribute three points. Ocular staining score ≥5 (or van Bijsterveld ≥4) in at least one eye, Schirmer ≤5 mm/5 minutes in at least one eye, and unstimulated whole saliva ≤0.1 mL/min each contribute one. The threshold is four. Thus, an SSA-negative patient with a qualifying biopsy and qualifying Schirmer test can reach the threshold; ACA plus all three one-point tests cannot. This illustrates the published framework, not a self-diagnosis calculator. [R02]
When the result remains uncertain, identify the uncertainty precisely: inadequate tissue, nonspecific chronic inflammation, medication-confounded secretion, or truly discordant objective tests. “Negative biopsy” without the pathology details is an incomplete description. Specialist review of an existing adequate specimen may be more informative than immediately repeating a procedure. A positive ultrasound can support further investigation while a normal study does not resolve every seronegative case.
Why reported prevalence varies
Ask what the denominator represents before interpreting a percentage. ACA frequency among classified Sjögren’s patients is different from the probability of Sjögren’s among people referred because ACA was found. Rheumatology, oral-medicine and pulmonary referral cohorts also select different clinical populations.
Assay choice, inclusion criteria, age distribution, ancestry, referral practice and exclusion of established overlap all affect the result. A CENP-B immunoblot cohort and a HEp-2 pattern-defined cohort should not be pooled without accounting for that difference. Requiring a positive biopsy in SSA-negative participants can itself enrich the sample for tissue disease.
The international evidence map below shows selected primary studies rather than a pooled prevalence estimate. Available data do not justify interpreting national differences as inherent biological differences between populations. The Argentine cohort below improves regional coverage without establishing a globally representative sample.
A useful denominator checklist asks: were all consecutive patients eligible, did everyone receive the antibody test, and were the same classification rules applied to each antibody group? A study that deliberately recruits ACA-only and SSA-only patients cannot estimate ACA prevalence in the underlying clinic. Likewise, a hospital cohort enriched for organ complications cannot directly describe community disease.
These issues are visible in newer Chinese studies. Zou’s comparison selected 53 ACA-only and 99 SSA-only patients; that composition is not a prevalence survey. [R22] Zhu’s multicenter analysis excluded established SSc and active PBC, limiting its ability to describe precisely the overlap phenotypes clinicians often want to understand. [R23] Larger sample size does not remove a selection rule. Report the rule before interpreting the percentage.
Glandular burden can be substantial
In SICCA, ACA was associated with more severe objective exocrine dysfunction despite lower frequencies of several conventional serological abnormalities. This cross-sectional association does not establish treatment response or predict the subsequent rate of gland failure. [R03]
The clinical implication is straightforward: reassuring systemic inflammatory markers do not establish adequate tear or salivary function. Measure the outcome relevant to the problem—ocular surface injury, secretion, dental complications, eating, sleep or recurrent swelling. Symptoms, secretion and structural findings may disagree and deserve to be described separately.
A person may need intensive dental prevention and ophthalmic treatment while having little measurable systemic activity. Another may have important systemic disease with modest dryness. These are compatible observations. See the existing professional glandular-care chapter and the four patient dryness guides for the detailed local-care pathway.
The cohorts do not support one uniform dryness rule. In SICCA, 82 of 1,361 classified participants had ACA. Adjusted odds of low unstimulated salivary flow and low Schirmer results were higher in the ACA group; these were measurements at evaluation, not rates of future deterioration. [R03] In KISS, ACA-positive patients reported worse oral dryness, yet the absolute Schirmer measurement was better and the frequency of low-flow findings did not differ clearly. [R16]
The practical response to disagreement is to measure the patient’s problem rather than choose the most dramatic group average. Distinguish aqueous tear deficiency from evaporative contributors, and perceived oral dryness from measured secretion. Record recurrent caries, candidiasis, difficulty tolerating food and whether swelling is diffuse or focal. Repeat function testing when the result could change a decision, using comparable collection conditions. A change in symptoms after a medication adjustment need not imply a change in autoimmune tissue injury.
Inflammation, tissue structure and fibrosis
A focus score quantifies focal lymphocytic inflammation in an appropriately assessed tissue sample; it does not directly quantify every component of damage or remaining function. Sample adequacy, background atrophy and correct recognition of focal lymphocytic sialadenitis affect interpretation.
The 2024 Japanese ultrasound study associated ACA with a higher study-specific ultrasound score. It used a scoring approach different from OMERACT, and not all structural abnormalities had a parallel difference in biopsy focus score. Ultrasound echogenic bands should not be translated into a precise histological fibrosis burden for an individual. [R06]
The apparently attractive sequence “ACA → fibrosis → irreversible dryness → antifibrotic treatment” contains several unproven steps. Tissue, ultrasound and functional measurements address related but distinct processes. A report should state which process was actually measured. Persistent dysfunction does not establish that all inflammation has disappeared, and inflammatory histology does not guarantee reversibility.
SICCA’s fibrosis comparison involved only 18 selected biopsies, six in each of three serological groups, and did not find a difference. That small comparison neither proves equivalence nor establishes universal excess fibrosis in ACA-positive glands. [R03] The ultrasound study also had missing data and used the Saxon test as a substitute for unstimulated flow in its classification approach. These measurement choices matter when comparing it with criteria-based cohorts. [R06]
For a patient with persistent dysfunction, ask what remains modifiable: surface inflammation, residual secretion, medication burden, obstruction or recurrent infection. Structural abnormality may explain a limited response, but should not become a reason to abandon symptom care. Conversely, trying increasingly potent immune therapy without a defined inflammatory target can expose a person to risk while leaving the dominant functional problem unchanged. A future fibrosis biomarker would need to predict an outcome beyond information already available from function, histology and imaging.
The broader clinical and immune phenotype
Describe arthritis, skin findings, neuropathic symptoms, cytopenias, immunoglobulins, complement and other abnormalities individually. The Japanese four-profile study and the Chinese anti-CENP-B cohort support serological heterogeneity rather than one uniform “mild ACA subtype.” [R05] [R07]
Lower average IgG or systemic activity in a selected group does not negate severe symptoms or a serious complication in one patient. ESSDAI addresses particular systemic activity domains; symptom burden and established damage are different dimensions. Do not reproduce a licensed instrument as an unlicensed site calculator.
When comparing groups, ask whether age, SSA status, comorbidities and referral setting explain part of the difference. Cross-sectional associations do not establish which antibody caused an organ finding. Likewise, an abnormal liver enzyme, reduced eGFR or low blood count should trigger the appropriate differential, not immediate attribution to ACA.
A useful assessment keeps four parallel records: symptoms and daily function; demonstrable inflammatory activity; established damage; and overlap/comorbidity. For example, severe fatigue, quiet inflammatory arthritis, persistent low saliva and treated obstructive sleep apnea can coexist. Compressing these into “active” or “inactive” disease loses the treatment question.
Zou’s selected inpatient study reported immune-cell and cardiac associations, but differences in age and selection complicate attribution; a diastolic filling measurement is not a diagnosis of pulmonary hypertension. [R22] Lei’s subgroup with “additional autoantibodies” included more than SSA alone. [R07] These studies support careful phenotyping, not a claim that one immune-cell count explains the whole syndrome. An unexpectedly abnormal result should be verified and interpreted against its own differential before it is made part of an ACA narrative.
Raynaud’s phenomenon and digital vascular findings
Characterize attacks: cold or emotional trigger, color change, pain, duration, symmetry, recovery and any tissue injury. Persistent discoloration, an ulcer or severe rest pain changes the urgency and the differential. Medication-induced vasoconstriction, large-vessel disease and other vascular disorders remain relevant.
Examine for puffy fingers, sclerodactyly, fingertip pits, telangiectasia and other evidence of systemic sclerosis. Nailfold capillaroscopy can help characterize the microvascular phenotype, but a nonspecific abnormality is not equivalent to a scleroderma pattern. The report should describe the finding and its clinical interpretation.
The useful question is whether the combined phenotype warrants a systemic-sclerosis pathway. A label such as “CREST” is insufficient when the actual components and organ assessment are unclear. Protecting digits and addressing symptomatic Raynaud’s are appropriate clinical targets even while diagnostic classification remains under review. [R08] [R09]
Describe capillaroscopy in terms of capillary enlargement, hemorrhage, density and architectural disorganization, with a specialist interpretation of whether an SSc pattern is present. An isolated tortuous vessel has a different meaning from a coherent pattern with capillary loss. The clinical examination and the quality of the study remain essential.
Treatment follows vascular severity. Thermal protection and removal of avoidable vasoconstricting exposures are a foundation. For clinically significant SSc-related Raynaud’s, a dihydropyridine calcium-channel blocker is a usual initial option; refractory disease may require a PDE5 inhibitor or intravenous prostanoid in specialist care. Digital ischemia requires assessment for tissue threat, infection and other vascular causes. Bosentan’s role in selected SSc patients is prevention of new digital ulcers, not a general treatment for ACA positivity or a promise of healing an existing ulcer. Blood pressure, interactions and tolerance constrain vasodilator choices. [R09]
Where Sjögren’s ends and systemic sclerosis begins
Systemic sclerosis requires a coherent clinical assessment. Its 2013 classification system includes skin, digital, microvascular, cardiopulmonary and antibody findings; ACA alone is insufficient. Absence of extensive skin thickening does not by itself exclude limited or sine-scleroderma disease. [R08]
| Current situation | Next question |
|---|---|
| ACA without established disease | Is the result analytically convincing, and are there objective clinical findings? |
| Established Sjögren’s, no SSc features | What baseline phenotype and organ function need documentation? |
| Raynaud’s plus suggestive examination or capillaroscopy | Does specialist assessment support an early SSc spectrum? |
| Established Sjögren’s/SSc overlap | Which surveillance and treatment recommendations apply to each disease? |
This is a branching assessment, not an inevitable progression ladder. Recording an uncertain diagnosis explicitly is preferable to either prematurely assigning SSc or repeatedly ignoring evolving objective findings.
An overlap assessment should produce a decision, not just a longer antibody list. If examination and capillaroscopy support an SSc spectrum, determine whether formal classification is met and whether organ evaluation is indicated despite limited skin findings. If they do not, record the baseline and the findings that would prompt reassessment. Uncertainty can be managed longitudinally without pretending it has already been resolved.
In SICCA, 14 of the 82 ACA-positive participants retrospectively met the newer 2013 SSc criteria despite exclusion of SSc by older criteria at enrollment. That is reclassification at assessment, not observed future conversion. [R03] It explains why apparently comparable “primary Sjögren’s” cohorts can contain different amounts of SSc-spectrum disease. When reading older studies, ask which criteria operated at entry and which were applied later.
Longitudinal risk: avoid the denominator trap
The Greek retrospective report is frequently summarized as a simple conversion percentage. Its detailed results describe two people initially presenting with ACA-positive Sjögren’s who later entered the SSc-with-sicca group. They should not casually be treated as two incident events within the separate final 20-person ACA-Sjögren’s group. [R04]
This illustrates why the original cohort construction matters. Retrospective reclassification, selected Raynaud’s cohorts, variable follow-up and older criteria can all change the apparent progression rate. A pooled collection of small reports is not a validated personal risk estimate.
Follow the phenotype: newly persistent puffy fingers, evolving skin change, a convincing capillaroscopic pattern or new cardiopulmonary findings may justify reassessment. The absence of these findings today should be documented without promising lifetime absence. VEDOSS observations arise from a specifically selected very-early-SSc context and should not be assigned to every incidental ACA result or ACA-positive Sjögren’s diagnosis. [R09]
An Argentine retrospective report adds a different perspective: among 207 Sjögren’s patients, 32 had Raynaud’s, 18 met the study’s very-early-SSc definition, and five of that selected subgroup developed limited SSc with ACA. Existing overlap at first assessment was excluded. This supports reassessment in a suggestive vascular phenotype; it does not supply a progression rate for all ACA-positive Sjögren’s patients. [R29]
The European VEDOSS registry similarly begins with Raynaud’s and features relevant to very early SSc. Its progression experience is informative for that enriched setting, not for an unselected positive blood test. [R28] To make future estimates transferable, studies need a clearly defined entry state, comparable surveillance, time at risk, losses to follow-up and competing outcomes. A single pooled percentage that omits these features can be less useful than a clearly documented clinical trajectory.
Lungs, DLCO and pulmonary hypertension
Distinguish airway disease, interstitial lung disease, pulmonary hypertension and pulmonary arterial hypertension. Reduced DLCO is a physiological finding with several causes, including anemia, parenchymal or vascular disease; its interpretation requires the rest of the pulmonary assessment.
For Sjögren’s, respiratory history belongs in routine review; baseline complete pulmonary function testing may be considered even without symptoms. Chronic cough or dyspnea warrants a more directed evaluation. Routine echocardiography is not the general recommendation for every asymptomatic Sjögren’s patient. [R10]
Established SSc changes the framework: the BSR guideline recommends annual PAH screening, with DETECT used in the appropriate population. That recommendation cannot be assigned solely because ACA is positive. Suspected pulmonary hypertension requires proper diagnostic confirmation and classification; echocardiography is not a substitute for hemodynamic confirmation when indicated. [R09]
The distinction prevents both missed disease and indiscriminate investigation. A new unexplained symptom overrides reassurance from an antibody subgroup average.
The ERS/EULAR guideline (first published online 2025; 2026 issue) adds risk-based imaging. In Sjögren’s with ILD risk factors—such as older age, male sex, active extrapulmonary disease or raised inflammatory markers—HRCT screening may be appropriate even without a symptom-only trigger. The recommendation is conditional and supported by low-certainty evidence; ACA alone is not a validated screening threshold. When HRCT is indicated, normal pulmonary function does not replace imaging. Established SSc has a broader HRCT screening recommendation. [R24]
| Clinical question | What the next assessment should distinguish |
|---|---|
| Persistent dry cough | Airway dryness or inflammation, reflux/aspiration, infection and interstitial disease |
| Low DLCO with preserved volumes | Test quality and hemoglobin effects, early parenchymal disease, emphysema or pulmonary vascular disease |
| Dyspnea with an abnormal echocardiogram | Probability and cause of pulmonary hypertension; need for expert assessment and right-heart catheterization |
| Established ILD with changing symptoms | Physiological or imaging progression, infection, embolic disease and other treatable complications |
For established Sjögren’s-associated ILD, the 2026 guideline suggests lung-function monitoring every 3–6 months in the first year and then every 6–12 months, with additional assessment for worsening; certainty is very low. These intervals concern diagnosed ILD, not every ACA-positive person. [R24] Decide jointly with pulmonary specialists whether inflammation, progression or another process is the treatment target.
For algorithm eligibility and evaluation outside it, see DETECT eligibility and the next pulmonary vascular assessment.
DETECT eligibility: a screening tool with boundaries
Once SSc is established, annual PAH risk assessment applies even if the patient feels well. The guideline population for DETECT is adults with SSc for more than three years, DLCO below 60% predicted and FVC at least 40% predicted. Disease duration is counted from the first non-Raynaud manifestation, not simply from the first cold-induced finger attack. An ACA-positive person with Sjögren’s alone does not enter this pathway solely because of the antibody. [R34] [R35]
DETECT combines clinical, laboratory, ECG and echocardiographic findings to identify patients needing right-heart catheterization. It is a screening algorithm, not a diagnosis of PAH. Its original high-risk study population also matters when interpreting performance outside the validated setting. [R35]
A patient with new SSc and DLCO of 58% should not be told to wait until the three-year threshold. Evaluate the abnormality now using symptoms, complete PFTs, hemoglobin, echocardiography and BNP/NT-proBNP, with pulmonary imaging and specialist referral as indicated. Catheterization answers the hemodynamic question when suspicion persists. A previously normal echocardiogram does not explain a new fall in gas transfer; a normal HRCT does not exclude pulmonary vascular disease. [R34]
Liver: PBC, AIH and alternative causes
Primary biliary cholangitis (PBC) affects small intrahepatic bile ducts. Autoimmune hepatitis (AIH) primarily raises a different diagnostic question about hepatocellular inflammation. ACA can coexist with autoimmune liver disease but is not a diagnostic substitute for the relevant biochemical, antibody and sometimes histological evidence. [R11]
First establish the pattern and persistence of abnormal tests. With disproportionate ALP elevation, clarify hepatic origin, consider GGT and evaluate obstruction and other cholestatic causes. AMA/AMA-M2 and, when relevant, PBC-specific antibodies inform the next step. Predominant aminotransferase elevation calls for its own assessment, including medications, metabolic disease, infection and AIH as appropriate.
Do not use one positive antibody to close the differential. Pruritus without a primary rash may be relevant but is nonspecific. Jaundice, dark urine or a worsening biochemical pattern warrants timely assessment. Management of confirmed PBC/AIH requires a liver-specific plan rather than a generic escalation of Sjögren’s therapy.
KISS provides direct, although small, ACA-specific clinical observations: autoimmune liver disease was recorded in six ACA-positive patients, including PBC, AIH and combined features. This is a reason to take an appropriate biochemical signal seriously, not to screen indefinitely for every possible liver diagnosis. [R16] In contrast, the incident PBC/AIH cases reported in Lei’s follow-up occurred in the CENP-B-negative group. Sparse events and different selection prevent either study from defining a universal ACA-specific liver risk. [R07]
For an individual, separate a clue, a working diagnosis and an established indication for treatment. A positive AMA with normal cholestatic enzymes raises a different question from persistent cholestasis with concordant serology. Mixed biochemical and immune findings may require hepatology assessment and biopsy to distinguish combined disease from a nonspecific antibody result. Recheck the current liver guideline when choosing medication; older PBC treatment lists should not be carried forward without a regulatory and indication review.
For the treatment decision, see when PBC can be diagnosed without biopsy and when to start UDCA.
When cholestasis is PBC: biopsy and the first treatment
The practical consequence of an AMA-positive cholestatic pattern is a liver-specific decision. Confirm that ALP is hepatic, review medications and competing causes, and image the biliary tree. When persistent cholestasis and PBC-specific antibodies agree and obstruction has been excluded, biopsy is usually unnecessary to establish PBC. An ALP of 1.5 times the upper limit of normal is not a universal minimum diagnostic threshold; it must not become a reason to dismiss a convincing presentation below that number. Conversely, AMA alone does not establish active PBC. [R11]
Biopsy becomes useful when the findings disagree or another process would change treatment, particularly suspected autoimmune-hepatitis overlap. Marked aminotransferase elevation, especially ALT above five times the upper limit, is a reason to revisit the diagnosis rather than simply escalate a generic autoimmune regimen.
Ursodeoxycholic acid, usually 13–15 mg/kg/day, is first-line treatment for PBC with abnormal liver enzymes. Evaluate biochemical response at approximately 12 months, while addressing pruritus and monitoring liver status separately. An early fall in ALP is encouraging but is not the entire treatment endpoint. Neither prednisone nor hydroxychloroquine replaces UDCA for uncomplicated PBC. [R11]
Dysphagia and reflux
Dryness can impair lubrication of food, but swallowing also depends on oropharyngeal coordination, esophageal motility and an unobstructed lumen. Clarify whether difficulty begins with initiating a swallow, occurs with solids or liquids, produces pain, or feels like food sticking after swallowing.
Reflux, candidiasis, structural narrowing, motility disease and neurologic causes may require different investigations. Established SSc increases concern for esophageal dysmotility, while ACA alone does not prove it. Tailor endoscopy, contrast studies, swallowing evaluation or manometry to the clinical question.
Progressive dysphagia, weight loss, bleeding or recurrent aspiration should not be managed as uncomplicated xerostomia. Inability to swallow secretions or an acute obstructed food bolus requires urgent care. Improving oral moisture may help comfort while a second mechanism still needs treatment. [R09] [R15]
The history should identify the anatomical question. Difficulty initiating swallowing with coughing or a wet voice raises concern about an oropharyngeal mechanism and aspiration. Progressive solid-food obstruction suggests a structural problem; difficulty with both solids and liquids can raise a motility question, although history alone does not establish the diagnosis. Odynophagia directs attention to mucosal injury or infection as well as other causes.
Improvement with saliva support helps identify a treatable contribution; it does not rule out coexisting disease. With reflux symptoms, consider meal timing, positioning and clinician-directed acid suppression while investigating alarm features. A proton-pump inhibitor treats acid exposure, not the underlying loss of motility. Record weight trajectory and nutritional impact, because a person may adapt so gradually that substantial swallowing impairment is initially described only as “I avoid dry foods.” [R09] [R15]
Other organs: resist antibody attribution
Renal tubular disease, immune-complex renal disease, neuropathy, inflammatory muscle disease and cardiac involvement belong to the systemic differential of Sjögren’s or an overlapping condition. There are insufficient ACA-specific data to turn ACA into a universal explanation or exclusion test for these problems.
Choose investigations according to findings: a urinalysis and renal/electrolyte assessment address a different question from nerve conduction studies, small-fiber evaluation or muscle enzymes. Medication toxicity, diabetes, nutritional deficiencies, compression and infection may compete with autoimmune explanations.
Before escalating immunosuppression, specify the suspected lesion, supporting evidence, immediate risk and measurable treatment objective. A biomarker-defined phenotype helps frame the assessment; it does not replace localization. The existing systemic atlas provides the broader organ routes. [R15]
Neuropathy requires localization. The peripheral nervous system guideline (first published online 2025; 2026 issue) distinguishes small-fiber symptoms, sensory ganglionopathy, large-fiber disease, vasculitic neuropathy and autonomic involvement. Normal routine nerve conduction studies do not exclude small-fiber neuropathy; selected patients may need skin biopsy or other specialist testing. Rapidly progressive, painful, asymmetric deficits raise a different urgency from stable distal tingling. Treatment evidence is often very low certainty and is not ACA-specific. [R25]
Renal findings need a mechanism. Hypokalemia with a non-anion-gap metabolic acidosis can suggest distal renal tubular acidosis; hematuria, proteinuria or declining filtration raises another renal differential. Severe weakness, arrhythmia or significant electrolyte disturbance requires prompt care. In established SSc, a new blood-pressure rise with kidney injury demands urgent assessment for renal crisis. These patterns are more actionable than repeatedly measuring ACA. [R09] [R15]
A neuropathic pain medicine, correction of an electrolyte deficit and treatment of immune-mediated nerve or renal injury serve different purposes. A good plan states which purpose applies before choosing the drug.
Related decisions: PBC diagnosis and first-line treatment · renal crisis in SSc overlap.
Lymphoma and long-term outcomes
Sjögren’s-associated lymphoproliferation deserves attention, but ACA is not a stand-alone lymphoma calculator. The often-cited Italian study concerned an explicitly selected ACA-positive SSc/Sjögren’s overlap population. Its conclusion cannot be generalized to isolated ACA-positive Sjögren’s or an incidental laboratory result. [R12]
Persistent focal gland enlargement, lymphadenopathy, unexplained systemic symptoms, purpura and concerning immune or hematologic findings require their own assessment. Neither a normal inflammatory marker nor the absence of SSA cancels a clinically suspicious lesion. Conversely, a positive ACA result does not justify telling a patient that cancer is expected.
The 2026 Chinese study did not detect significant differences in its major outcome comparisons. Its selected single-center population, event counts and unadjusted survival comparisons limit reassurance; statistical nonsignificance is not equivalence. [R07] Risk assessment must integrate the actual phenotype and longitudinal change.
Persistent major-gland swelling deserves particular attention when accompanied by low C4, cryoglobulins, a monoclonal component, purpura or lymphadenopathy. These are disease-context clues, not proof of malignancy. Investigation should characterize the lesion and obtain tissue when indicated; serial ACA measurements cannot answer whether a focal mass is lymphoproliferative. [R15]
Distinguish recurrent bilateral inflammatory swelling from a persistent focal or asymmetric change, while recognizing that appearance alone cannot establish the cause. Ultrasound can help direct further evaluation; a suspicious lesion may require specialist sampling that preserves enough material for the relevant pathology. Avoid using a low symptom score to overrule a new mass. Conversely, this evidence does not establish an ACA-only indication for repeated whole-body imaging in an otherwise unchanged patient. The purpose of surveillance is to recognize meaningful change and investigate it appropriately, rather than to promise that a screening test can eliminate future risk.
Treat symptoms and preserve function
Set separate goals for ocular comfort, surface protection, oral function, dental prevention and systemic inflammation. Local measures remain relevant even when systemic treatment works well. They should not be withdrawn merely because an antibody titer falls.
For dryness, treatment depends on the affected surface, residual secretion, complications and tolerance. Lubrication, ophthalmic anti-inflammatory treatment, selected secretagogues and dental prevention have different purposes. The detailed glandular-care chapter explains these choices and their evidence.
Fatigue, widespread pain and sleep disturbance require mechanism-based assessment. A single symptom score cannot establish active organ inflammation, and a low systemic score does not invalidate the symptom burden. Ask what treatment will change and how benefit will be recognized. No direct evidence reviewed here supports immunosuppression solely to make ACA negative. [R14] [R15]
| Dominant problem | Treatment purpose | Evidence of useful benefit |
|---|---|---|
| Tear-film or surface disease | Lubrication and, when indicated, ophthalmic anti-inflammatory therapy | Surface healing, visual function, comfort and tolerability |
| Oral dryness with residual secretion | Saliva stimulation when suitable, or replacement for comfort | Eating, speaking, sleep and practical tolerability |
| Dental vulnerability | Fluoride-based prevention and individualized dental care | Fewer new lesions and maintenance of dentition |
| Recurrent local infection | Confirm and treat the infection; address predisposing factors | Resolution of the lesion, not a change in ACA |
| Fatigue or widespread pain | Identify sleep, activity, pain and medical contributors | Function and achievable daily goals |
Pilocarpine or cevimeline, where available and appropriate, stimulates residual secretion; sweating and other cholinergic effects can limit use. Suitability depends on comorbidity and contraindications. Prescription ocular treatment and procedures require eye assessment rather than selection by antibody profile. [R14] [R15] The same medicine can be a reasonable trial for one patient and a poor fit for another. Agree in advance what benefit would justify continuing it, and retain preventive care even if symptom relief is incomplete.
Systemic therapy and overlap-specific hazards
Systemic treatment should follow the organ lesion, severity, activity, reversibility and competing risks. Evidence from Sjögren’s trials is not automatically evidence for an ACA-defined subgroup. A drug chosen for inflammatory arthritis, vasculitic neuropathy or ILD may have little effect on established dryness.
Confirmed overlap changes treatment choices. In SSc, glucocorticoid exposure requires particular caution because of renal-crisis risk; a Sjögren’s treatment habit should not be carried into SSc without reassessing that risk. Pulmonary vasodilators, antifibrotics and liver-directed agents require their own indications. [R09]
The molecular presence of TGF-β activity does not establish a clinical indication for an antifibrotic. Similarly, B-cell activity in tissue does not identify the best B-cell therapy for one patient. Treatment remains a decision about demonstrated disease, not antibody suppression as an end in itself.
| Demonstrated treatment target | Examples considered in clinical practice | Important boundary |
|---|---|---|
| Selected inflammatory musculoskeletal or systemic features | Hydroxychloroquine; methotrexate for a suitable inflammatory arthritis phenotype | Neither is a treatment to normalize ACA or reliably restore secretion |
| Clinically significant inflammatory ILD | Specialist-directed immunosuppression, often a steroid-sparing agent such as mycophenolate | Evidence and choice depend on the lung phenotype; the SjD-specific evidence base is limited |
| Severe immune-complex/cryoglobulinemic disease or selected refractory systemic disease | Rituximab within an organ-specific plan | Evidence does not support routine use for uncomplicated dryness |
| Rapidly progressive vasculitic neuropathy | Urgent specialist treatment; the PNS guideline includes glucocorticoids plus rituximab | Mostly very-low-certainty guidance; SSc overlap changes steroid-risk assessment |
| Progressive fibrosing lung disease | Antifibrotic consideration under the applicable pulmonary pathway | A glandular TGF-β signal does not establish this indication |
These examples connect treatment to a lesion; they are not a prescribing ladder for ACA. [R14] [R15] [R24] [R25] Hydroxychloroquine’s limited trial results for broad symptom endpoints should not be converted either into a promise of relief or a claim that it has no selected clinical role. Before a treatment trial, specify the target, time for reassessment and reasons to stop, change or escalate. Infection prevention, vaccination, laboratory monitoring and reproductive planning follow the actual medicine and patient context.
For urgent overlap-specific decisions, see renal crisis: ACE inhibition, blood-pressure timing and steroid withdrawal.
Renal crisis in overlap disease: the first hours matter
New hypertension with acute kidney injury in established SSc requires urgent assessment for scleroderma renal crisis. Thrombocytopenia, schistocytes and raised LDH strengthen concern for thrombotic microangiopathy. The usual ACA-associated phenotype lowers the background probability; it does not safely exclude the diagnosis. Assess competing causes when indicated without delaying treatment of a convincing crisis.
Start or intensify an ACE inhibitor promptly, with nephrology and close hemodynamic monitoring. Captopril is useful when short action and frequent titration are desirable, particularly in cardiovascular instability; a long-acting ACE inhibitor is also acceptable. There is no universal requirement to choose captopril. Additional antihypertensives may be needed. [R09] [R31]
The often-quoted period of roughly 72 hours is not permission to defer treatment of acute organ injury. Hypertensive encephalopathy or cardiac decompensation requires prompt, controlled blood-pressure reduction in a monitored setting. When these complications are absent, a steadier reduction can better preserve renal perfusion. Headache, blurred vision or retinal hemorrhages require immediate assessment of that distinction. The pace follows the patient’s condition, not an inflexible timetable. [R31]
The classic case-control study associated prednisone-equivalent exposure of at least 15 mg/day with renal crisis; this is an observational risk signal, not a proven safe-dose boundary below 15 mg. Current BSR guidance advises caution above 10 mg/day and minimizing glucocorticoids in adults with SSc. Confirm an inflammatory treatment target and consider appropriate steroid-sparing therapy rather than treating puffy hands automatically with high-dose prednisone. [R32] [R09]
Reducing steroid exposure does not replace ACE inhibition. A two-week oral course alone does not generally require tapering for adrenal protection: endocrine guidance permits stopping courses shorter than three to four weeks. Prior courses, concurrent inhaled or other formulations, adrenal-risk features and the underlying indication can change that decision. A clinical taper for ongoing inflammation is a separate rationale from a claim that every two-week course suppresses the adrenal axis. [R33]
A follow-up plan that answers real questions
| Finding | Clinical question | Assessment that may answer it | What could change |
|---|---|---|---|
| New Raynaud’s or puffy fingers | Is an SSc phenotype emerging? | Examination, capillaroscopy, targeted review | Diagnostic and organ-surveillance pathway |
| Falling exercise tolerance or DLCO | Airway, parenchymal, vascular, cardiac or other cause? | Complete physiology and directed cardiopulmonary evaluation | Need for organ-specific treatment |
| Persistent cholestatic tests | PBC, obstruction, medication or another cause? | Biochemical confirmation, relevant antibodies and imaging | Hepatology route and treatment |
| Focal gland enlargement | Obstruction, infection, inflammation or lymphoproliferation? | Clinical assessment, imaging, sampling when indicated | Urgency and definitive diagnosis |
| Worsening dryness with stable systemic tests | Surface damage, low secretion or another mechanism? | Ophthalmic/oral evaluation | Local prevention and symptom treatment |
This matrix is clinical synthesis, not a universal test order. At baseline, document what is established, uncertain and already measured. Review interval follows organ risk, activity, treatment and new symptoms. Serial ACA titers are not a validated substitute for measuring organ function or examination findings.
A baseline summary is most useful when it can be compared with the next visit. Include the antibody methods; evidence supporting Sjögren’s and any overlap; ocular and oral complications; vascular examination; relevant organ measurements; and the purpose of each current treatment. An isolated list of normal tests without dates or a reason for ordering them is harder to use.
Separate three clocks: monitoring a prescribed drug, monitoring a known organ lesion, and reviewing an otherwise stable phenotype. They need not have the same interval. For a stable person without organ disease, this chapter does not impose a universal ACA schedule. For established ILD, the organ-specific intervals above provide a starting framework. For a new warning symptom, waiting until an annual visit is inappropriate. [R15] [R24]
At reassessment, ask “What changed, and could it change management?” Persistent antibody positivity without a new clinical question is different from new breathlessness, progressive weakness or focal gland enlargement. The latter findings require their own route even when the last routine panel was reassuring.
Pregnancy and different life stages
Anti-Ro/SSA and anti-La/SSB have specific reproductive implications that should not be reassigned to ACA alone. Preconception review also considers disease activity, cardiopulmonary and renal function, blood pressure, medications and any established overlap. [R13]
A patient with ACA+/SSA+ needs counseling that recognizes the SSA result as well as the clinical phenotype. A patient with isolated ACA does not automatically belong to an anti-Ro fetal-surveillance pathway. An incomplete panel is a reason to clarify which antibodies were measured, not to infer absence.
Evidence in children, men and unusual age-at-onset groups is comparatively limited. Adult female referral-cohort findings should not be presented as equally precise for those populations. Older age also increases competing causes of dryness and cardiopulmonary symptoms; assessment must keep both autoimmune disease and comorbidity in view.
For the person who will carry the pregnancy, medication planning is part of disease control. Hydroxychloroquine is generally compatible with pregnancy, whereas methotrexate and mycophenolate require advance discontinuation and a planned alternative when treatment remains necessary. Drug-specific timing and contraception should be reviewed with the treating team; stopping effective therapy without a replacement can also create risk. The EULAR 2024 update, published in 2025, also supports distinguishing pregnancy-compatible treatment from medicines requiring advance discontinuation. Paternal exposure and breastfeeding need their own drug-specific assessment. Anti-Ro/La-positive pregnancy warrants coordinated counseling and a fetal assessment plan appropriate to history and local specialist practice. [R13] [R30]
Established pulmonary hypertension or major cardiopulmonary disease changes reproductive counseling far more than an isolated ACA result. Likewise, antiphospholipid antibody assessment answers a separate question; the abbreviation ACA should never lead to accidental substitution of anticentromere for anticardiolipin results. At other life stages, re-evaluate competing medication and age-related contributors rather than assuming every new symptom reflects evolution of the original autoimmune phenotype.
For a medication transition after renal crisis, see preconception planning with nephrology and maternal-fetal medicine.
Pregnancy after renal crisis: replace the plan before the prescription
After renal crisis, preconception review needs a written agreement between rheumatology, nephrology and maternal-fetal medicine. Reassess renal recovery, blood pressure, current disease activity and cardiopulmonary status, including an up-to-date PAH assessment. An arbitrary anniversary after the crisis does not itself establish readiness: the decision depends on organ stability and a sustainable treatment plan. [R09]
Methotrexate must be discontinued before pregnancy. Azathioprine is pregnancy-compatible and can be considered when it is appropriate for the condition being treated, but this is not an automatic equivalent substitution for every methotrexate indication. Choose the replacement, allow time to assess control and monitor it according to usual practice. Underlying PBC also makes hepatology input relevant. A three-month lead-in may be the team’s individual plan; it is not a universal rule that every patient must receive azathioprine for exactly that interval. [R30]
ACE inhibitors can cause serious fetal injury, particularly through fetal renal effects in later pregnancy. Routine guidance is to stop them promptly once pregnancy is confirmed and provide an appropriate alternative; exceptional maternal indications require specialist decisions. A history of renal crisis makes an unsupervised drug withdrawal unsafe, but it does not make fetal exposure harmless. Decide the conception, testing and medication-transition plan in advance, including who will respond immediately to a positive pregnancy test. [R36]
International evidence: what each study can answer
| Primary study | Population and design | Useful contribution | Main limit for this chapter |
|---|---|---|---|
| Baer, SICCA, 2016 [R03] | International cross-sectional Sjögren’s cohort; HEp-2 ACA | Objective glandular dysfunction association | Cross-sectional association cannot establish future damage or treatment response |
| Bournia, Greece, 2010 [R04] | Retrospective groups defined by Sjögren’s, SSc and ACA | Phenotype and changing diagnostic labels | Final-group denominators complicate simple conversion estimates |
| Tsukamoto, Japan, 2018 [R05] | Retrospective, four ACA/SSA groups | Separates ACA-only and double-positive profiles | Methods report 601 enrolled; results analyze 585; other rheumatic disease excluded |
| Park, Korea/KISS, 2021 [R16] | Analysis within a prospective Korean cohort | Vascular, immune and liver associations | Findings from a single national cohort require attention to selection, assays and outcome definitions |
| Shimizu, Japan, 2024 [R06] | Ultrasound and clinical association study | Connects ACA with structural gland findings | Study-specific imaging score; association is not histologic proof |
| Inamo, Japan, 2025 [R17] | Biopsy-based single-cell and spatial work | Mechanistic heterogeneity | Small groups; CENT inclusion permits modified research criteria, as explained below |
| Lei, China, 2026 [R07] | 1,222 analyzed; 100 anti-CENP-B-positive; follow-up cutoff February 2024 | Distinguishes baseline profile from observed outcomes | Other CTDs excluded; referral selection, missing data and limited prognostic inference |
These studies are not independent tests of one identical hypothesis. Cohort overlap is possible, definitions differ, and not all studies address prospective outcomes. No synthetic personal percentage is calculated. The evidence map is selective and should expand as additional regional and longitudinal data become available.
| Additional primary source | What it adds | Why interpretation remains bounded |
|---|---|---|
| Martínez Perdomo, Argentina, 2025 [R29] | Sjögren’s/Raynaud’s and very-early-SSc observations | Retrospective, selected vascular subgroup; not a risk estimate for all ACA-positive people |
| Zou, China, 2025 [R22] | Direct ACA-only versus SSA-only comparison | Selected hospital population; excludes the other serological combinations from that comparison |
| Zhu, China, 2026 [R23] | Multicenter description and a machine-learning classifier | Target is current ACA status; split-sample performance does not establish future clinical prediction |
| European VEDOSS registry [R28] | Longitudinal early-SSc context | Entry phenotype differs from unselected Sjögren’s or incidental ACA |
An evidence hierarchy for this question. A cross-sectional study can support an association; a longitudinal cohort can describe observed outcomes; an externally validated prognostic model can estimate risk in a matched setting; a randomized trial can estimate a treatment effect in its enrolled population. None automatically supplies the next level. There is still no validated ACA-only tool in this chapter for predicting an individual’s SSc conversion, gland decline or drug response.
Source access also has levels. Full-text methods were checked for the central gland, phenotype and molecular studies; the older overlap report remains abstract-based, so no detailed lymphoma event estimate is reproduced. The map is a critical selection of accessible primary evidence, not a systematic review or an assertion of exhaustive geographic coverage.
Molecular findings: promising questions, unfinished causal links
Inamo’s single-cell analysis included 19 antibody-positive patients (8 SSA, 7 CENT and 4 co-positive) plus 8 sicca controls; the spatial analysis used a partly overlapping, smaller set. Shared cytotoxic T-cell expansion accompanied relatively stronger interferon findings in SSA and TGF-β/epithelial–mesenchymal/fibroblast findings in CENT. Interferon signaling was not absent in CENT. Crucially, CENT inclusion permitted either standard criteria or a research modification counting CENT as an autoantibody item. Controls had sicca but did not meet the specified Sjögren’s criteria; they were not a classified double-negative Sjögren’s comparison group. These small, selected tissue groups support hypotheses, not an ACA-based treatment rule. Thousands of cells do not become thousands of independent patients. Main-text methods were verified; supplementary files were not obtained. [R17]
Three questions remain distinct. Does an antibody profile identify a reproducible biological subgroup? Does the associated pathway contribute causally to disease? Does targeting that pathway improve a meaningful outcome in the subgroup? An affirmative answer to the first does not establish the other two.
Research comparing centromere epitopes is likewise not a validated clinical method for distinguishing future SSc from stable Sjögren’s. Biomarker development needs independent replication, prospective prediction and evidence that acting on the result improves care. A stronger biological rationale can justify a trial while leaving current prescribing unchanged.
A practical test of a mechanistic claim. Ask whether the signal is replicated in independent patients, whether differences persist after relevant clinical and technical adjustment, and whether the proposed pathway predicts a functional outcome. Then ask whether changing that pathway changes the outcome. A pathway that is more prominent in one tissue group can still be shared across groups, and a blood antibody may mark rather than cause the difference.
Machine learning does not remove those requirements. Zhu’s model used a random training/validation split to distinguish current ACA status in the studied population. It was not an externally validated model of future SSc, PBC or lymphoma. A SHAP feature ranking describes contributions to that fitted model, not biological causation. [R23] The clinical question is whether a model adds useful information beyond directly measuring the antibody and examining the patient. Until that is demonstrated, attractive discrimination metrics should not be presented as an actionable prognosis.
Trials: inclusion is different from demonstrated subgroup benefit
| Program | Mechanism / question | Serological eligibility found in primary records | Meaning for ACA |
|---|---|---|---|
| Ianalumab NEPTUNUS-2, NCT05349214 [R18] | BAFF-R-directed B-cell treatment | SSA generally required; SSA-negative participants allowed with centrally confirmed positive salivary biopsy, capped at 10% in the checked record | ACA+/SSA− is not categorically excluded; ACA alone is insufficient and actual ACA enrollment/subgroup benefit remains a separate question |
| Dazodalibep NCT06104124 / NCT06245408 [R19] [R20] | CD40L; systemic activity and symptom-focused programs | Anti-Ro or RF positivity | SSA−/ACA+ with RF may satisfy this component; ACA alone does not satisfy it |
| Nipocalimab DAHLIAS [R21] | FcRn; active disease | Anti-Ro IgG-positive population | Results cannot establish response in an isolated ACA+/SSA− population |
This NEPTUNUS-2 statement uses the ClinicalTrials.gov record updated 17 June 2026. The biopsy exception corrects an overbroad SSA-required description based on the earlier indexed registry material; do not assume every ianalumab protocol or country record uses identical wording. Other entry criteria, organ exclusions and local recruitment still apply. This is an eligibility comparison, not a claim that recruitment is currently open or that a medicine is approved for this indication. No ACA-specific randomized efficacy estimate was identified in the records assessed for this edition.
For CD40, BAFF/APRIL, kinase, cellular and local gland approaches, the same questions should precede extrapolation: was the ACA profile allowed, actually enrolled, reported and analyzed? Absence of a subgroup result is uncertainty, not evidence of ineffectiveness. An adequate future trial should report the relevant antibody combinations and functional outcomes, not simply an undifferentiated “autoantibody-positive” label.
| Additional program | Verified population feature | Implication for this phenotype |
|---|---|---|
| Iscalimab TWINSS, anti-CD40 [R26] | Registry required anti-SSA; activity and symptom cohorts had distinct entry criteria | Results do not establish benefit in ACA-only/SSA-negative disease |
| Telitacicept, BAFF/APRIL-directed [R27] | Phase 2 enrolled anti-SSA-positive patients with systemic activity; phase 3 NCT07404865 also requires SSA | Promising Sjögren’s research does not remove the representation gap |
The live registry records for the two dazodalibep studies were inspected on 22 September 2026. Their anti-Ro-or-RF rule is only one eligibility component: the programs distinguish systemic activity from high symptom burden, and the symptom study excludes systemic sclerosis. [R19] [R20] Thus, “SSA-negative but RF-positive” is not equivalent to “eligible,” particularly with overlap disease. The telitacicept phase 3 record likewise has organ and competing-disease restrictions. [R27]
An informative ACA study would prespecify ACA-only and ACA/SSA co-positive strata, describe assay methods and SSc overlap, and select outcomes that match the intervention. A gland-restoration question needs function and patient benefit; a vascular intervention needs vascular outcomes. Merely adding ACA to an enrollment table does not solve a subgroup analysis that is too small to interpret.
Six difficult situations
These are invented educational scenarios, not individual patient recommendations. Each uses the same sequence: define the missing fact, obtain information that can change a decision, select a target and reassess that target.
Severe dryness, ACA+/SSA−, no biopsy. First establish objective eye and oral findings and review drying medicines and the SSA assay. If classification or a consequential diagnostic decision remains unresolved, discuss an adequate labial biopsy and its limitations. A qualifying biopsy with an objective one-point test can meet the research threshold; ACA supplies no missing points. Start protection of the eye surface and teeth while the diagnosis is clarified. The immediate endpoint is function and prevention of injury, not waiting for every label to be settled. [R02]
ACA+/SSA+, fatigue and normal routine inflammatory markers. Look for a specific inflammatory lesion while assessing sleep, pain, anemia, medication burden and daily function. Do not add the two antibody profiles into an imagined severity score. If there is no treatment-responsive inflammatory target, agree on a symptom and function plan rather than escalating immune therapy by serology. If examination identifies synovitis or another organ lesion, manage that finding and measure its response separately from fatigue.
ACA with Raynaud’s and a vague capillaroscopy report. Obtain the actual images or specialist interpretation and examine for puffy fingers, pits, ulcers, telangiectasia and skin change. A convincing SSc pattern changes the diagnostic and organ-assessment question; a nonspecific report does not settle it. Treat clinically significant vascular symptoms and explain when persistent pain or discoloration requires urgent care. Reassessment concerns new objective features, not a rising ACA number.
ACA with persistent ALP elevation. Verify the pattern and hepatic origin, review medicines and investigate biliary obstruction and relevant autoimmune serology. Distinguish PBC from AIH, mixed disease and common alternatives. The decision is whether there is an established liver diagnosis requiring a liver-specific plan. Repeatedly labeling the result “autoimmune” without defining the lesion can delay effective treatment.
ACA with reduced DLCO. Check measurement quality, hemoglobin and accompanying physiology, then relate the result to symptoms, imaging and whether SSc is established. Normal lung volumes do not by themselves exclude interstitial or vascular disease. Directed HRCT and/or cardiac assessment may be needed; suspected pulmonary hypertension requires appropriate confirmation. The endpoint is an explained physiological abnormality and a plan for the identified disease, not a pulmonary-hypertension label assigned from ACA alone. [R09] [R24]
Incidental ACA without sicca or SSc findings. Review the original result and its analytical credibility, then document a focused history and examination. If no disease is established, explain that explicitly and identify useful triggers for reassessment, such as new Raynaud’s, persistent finger swelling or unexplained breathlessness. No evidence in this chapter supports preventive immunosuppression solely for the antibody. A clear baseline and proportionate follow-up can be meaningful care even when no medicine is prescribed.
Sources
- [R01] ICAP: AC-3 centromere pattern
- [R02] 2016 ACR/EULAR classification criteria for Sjögren’s
- [R03] Baer et al. SICCA: ACA and exocrine dysfunction (2016)
- [R04] Bournia et al. ACA-positive Sjögren’s: retrospective analysis (2010)
- [R05] Tsukamoto et al. Four ACA/SSA profiles (2018)
- [R06] Shimizu et al. ACA and salivary-gland ultrasound (2024)
- [R07] Lei et al. Anti-CENP-B: phenotype and outcomes (2026)
- [R08] 2013 ACR/EULAR systemic-sclerosis classification criteria
- [R09] BSR systemic-sclerosis guideline (2024)
- [R10] Sjögren’s Foundation: pulmonary clinical practice guidance
- [R11] AASLD primary biliary cholangitis practice guidance
- [R12] Baldini et al. ACA-positive SSc/Sjögren overlap (2013)
- [R13] ACR reproductive-health guideline (2020)
- [R14] EULAR topical and systemic Sjögren’s treatment recommendations
- [R15] BSR adult and juvenile Sjögren disease guideline (2024/2025)
- [R16] Park et al. ACA in the Korean KISS cohort (2021)
- [R17] Inamo et al. Single-cell and spatial profiling of Sjögren’s (2025)
- [R18] Ianalumab NEPTUNUS-2: NCT05349214, record updated 17 June 2026
- [R19] Dazodalibep systemic-activity study NCT06104124
- [R20] Dazodalibep symptom study NCT06245408
- [R21] Nipocalimab DAHLIAS primary trial report (2025)
- [R22] Zou et al. ACA-only versus SSA-only Sjögren’s (2025)
- [R23] Zhu et al. Multicenter ACA phenotype and machine-learning analysis (2026)
- [R24] ERS/EULAR connective tissue disease-associated ILD guideline (first published online 2025; 2026 issue)
- [R25] Deboo et al. Peripheral nervous system manifestations in Sjögren’s: guideline (first published online 2025; 2026 issue)
- [R26] Iscalimab TWINSS: trial report (2024) and NCT03905525 · https://pubmed.ncbi.nlm.nih.gov/39096929/
- [R27] Telitacicept: phase 2 report and phase 3 NCT07404865 · https://pubmed.ncbi.nlm.nih.gov/37399108/
- [R28] Bellando-Randone et al. VEDOSS five-year registry analysis (2021)
- [R29] Martínez Perdomo et al. Sjögren’s, Raynaud’s and development of SSc: Argentina (2025)
- [R30] EULAR antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update (2025)
- [R31] UK Scleroderma Study Group: diagnosis and management of scleroderma renal crisis (2016)
- [R32] Steen and Medsger: corticosteroid exposure and renal crisis, matched case-control study (1998)
- [R33] ESE/Endocrine Society: glucocorticoid-induced adrenal insufficiency guideline (2024)
- [R34] ESC/ERS: pulmonary hypertension guideline, SSc screening recommendations (2022)
- [R35] Coghlan et al.: DETECT study (2014) · CTD-associated PAH screening consensus: duration from first non-Raynaud symptom (2013)
- [R36] BSR prescribing in pregnancy: comorbidity medications, ACE inhibitors (2023)
Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.